News Room
News Room
News Room
Harmony Biosciences to Acquire Zynerba Pharmaceuticals, Inc.
Acquisition expands pipeline and diversifies portfolio to drive long-term growth Innovative potential new therapeutic option for rare/orphan neuropsychiatric disorders with high unmet medical needs [...]
Harmony Biosciences Announces Jeffrey M. Dayno, M.D. Appointed President & Chief Executive Officer
– Dr. Dayno joins Harmony Biosciences Board of Directors – PLYMOUTH MEETING, PA, April 24, 2023 – Harmony Biosciences Holdings, Inc. (“Harmony” or the [...]
Emalex Biosciences Announces First Patient Dosed in Phase 3 Trial of Ecopipam for Tourette Syndrome
– Enrolled patients will receive medication for up to 24 weeks; 90 sites planned for North America and Europe – CHICAGO, March 1, 2023 [...]
Harmony Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
WAKIX® (pitolisant) Net Revenue Increased ~41% Year-over-Year to $128.3 Million for Fourth Quarter 2022; ~43% to $437.9 Million for Full Year 2022 Achieved Net [...]
Evozyne Creates AI Model with NVIDIA for Novel Protein Design, Expected to Accelerate Drug Development
– New AI model, co-developed by Evozyne and NVIDIA, can create novel therapeutic proteins for a new era of drug development – CHICAGO—January 12, [...]
Emalex Biosciences Publishes Phase 2b Results for Tourette Syndrome Candidate in Pediatrics
– Study data shows investigational new drug, ecopipam, reduced total number of tics by 30% compared to placebo – CHICAGO—January 11, 2023 – A [...]
